Our findings reinforce the central role of TNF-α signaling and mitochondrial dysfunction in AD and PD pathology and support the potential therapeutic relevance of GLP-1R agonists, particularly in restoring energy homeostasis and reducing neuroinflammation. This evidence concerns the gene GLP1R and Parkinson disease.